BeiGene prices second HK biotech IPO near top
BeiGene priced its IPO in Hong Kong near the top end of guidance on Thursday, raising HK$7.1bn ($903m) from the city’s second biotechnology flotation.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: